Retatrutide news and clinical trials

Phase 3 trials TRIUMPH-1-OSA and TRIUMPH-2-OSA found that once-weekly retatrutide significantly reduced the apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea compared to placebo.

A study in streptozotocin-induced diabetic rats found that retatrutide significantly lowered HIF-1α expression in kidney tissue but did not provide statistically confirmed histopathological protection against renal injury.

A cross-sectional study in JAMA Network Open evaluates self-reported adverse effects among social media users who utilized nonapproved retatrutide.

A JAMA article outlines the risks and reasons behind the growing black market for unapproved GLP-1 weight loss drugs, including retatrutide and zenagamtide.

Researchers published an article in The Lancet discussing findings from the TRIUMPH-2 clinical trial regarding retatrutide in adults with obesity and type 2 diabetes.

A BMJ case report details a woman who experienced persistent nausea and vomiting after self-administering unverified retatrutide injections obtained from a non-medical practitioner. The Naranjo score of 7 indicated probable causality.

A report in the BMJ indicates that retatrutide, a triple hormone receptor agonist, demonstrated the potential to cause weight loss of up to 25% in clinical trials.

A phase 3 trial in the New England Journal of Medicine found that adults with obesity who received weekly retatrutide injections for 80 weeks achieved weight reductions of up to 25.0%, compared to 3.9% in the placebo group. The drug also improved symptoms of knee osteoarthritis and sleep apnea.

The phase 3 TRIUMPH-2 trial, which enrolled 1152 participants with obesity and type 2 diabetes, assessed the efficacy and safety of once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg versus placebo.

A narrative review in Biomedicines discusses the potential for using retatrutide to address metabolic dysfunction in patients with schizophrenia treated with clozapine or olanzapine. The authors note that no clinical trials have yet tested the drug in this specific population.

Researchers published a study showing that daily co-administration of cagrilintide and retatrutide in diet-induced obese male rats produced greater weight loss and improved metabolic markers compared to monotherapies or combinations with semaglutide or tirzepatide.

Researchers developed a method to detect retatrutide in human plasma and urine using mass spectrometry. The study found that plasma is the appropriate matrix for detection, offering an extended window of approximately 56 days after the first dose.

A case report in Cureus describes a patient with type 1 diabetes who developed severe symptoms and ketonaemia after self-administering an online-purchased product marketed as retatrutide. The authors highlight the dangers of using unregulated research peptides.

A study in iScience compared the effects of semaglutide, tirzepatide, and retatrutide on renal fibrosis in mice and cell models. Retatrutide demonstrated the greatest efficacy at the tested doses in mitigating fibrosis and inflammation.

A post hoc analysis of phase 2 trials in adults with obesity found that retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.

The BMJ reports that retatrutide has become available for compassionate use in the United States.

A letter in Drug and Alcohol Review assesses the composition and labeling accuracy of various products sold as retatrutide within Australia.

A study in the journal Lab Animal examined the effects of retatrutide on cognition in diabetic rats.

A letter published in the European Journal of Internal Medicine discusses the timing of urinary tract infection signals in relation to retatrutide use.

The BMJ published a fact check investigating claims regarding the death of a person following the use of an unapproved weight loss injection.

A study in Behavioural Brain Research indicates that retatrutide partially attenuates streptozotocin-induced behavioural and neuroinflammatory changes in diabetic rats. The drug reduced blood glucose and hippocampal inflammation but did not fully normalize all memory measures.

A meta-analysis published in High blood pressure & cardiovascular prevention found that retatrutide treatment significantly decreases systolic and diastolic blood pressure, as well as total cholesterol, LDL-C, and triglyceride levels.

Eli Lilly and Company completed a Phase 3 study evaluating the efficacy and safety of once-weekly retatrutide in 1152 participants with Type 2 diabetes and obesity or overweight. The study included a subset of patients with obstructive sleep apnea and lasted about 89 weeks.

A clinical trial report indicates that Retatrutide functions as a triple-acting treatment for type 2 diabetes. The study found it lowers blood sugar levels and promotes weight loss.

New randomized trial in Lancet (London, England): Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised….

Eli Lilly and Company registered an expanded access program for retatrutide to provide treatment for adults with severe obesity and at least two serious or life-threatening complications. Candidates must have a BMI ≥35 kg/m² and be unable to join an ongoing clinical trial.

Researchers published a new method for synthesizing the triple agonist Retatrutide called hydrophobic tag-assisted liquid-phase peptide synthesis (LPPS). This approach serves as a more efficient and scalable alternative to traditional solid-phase peptide synthesis.

Eli Lilly and Company completed a Phase 3 trial of once-weekly retatrutide in 1946 participants with obesity and established cardiovascular disease. The study evaluated the efficacy and safety of the medication over approximately 113 weeks.

An exploratory analysis of phase 2 trials found that retatrutide treatment was associated with changes in metabolic clusters related to fatty acid oxidation and insulin resistance in a direction consistent with improved metabolic health.

A comprehensive review of Retatrutide clinical data highlights its effectiveness in treating cardiovascular-kidney-metabolic syndrome. Participants receiving a 12-mg dose showed a 24.2% total body weight reduction at 48 weeks and significant improvements in liver fat and blood pressure.

Eli Lilly and Company completed a Phase 1 study involving 80 participants to measure the effect of weekly retatrutide versus placebo on recovery time from hypoglycemia. The assessment followed 16 weeks of treatment.

Eli Lilly and Company completed a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide in 2335 participants with obesity or overweight. The study also included subsets of participants with knee osteoarthritis and obstructive sleep apnea.

Scientists found that Retatrutide alleviates adipose tissue fibrosis in high-fat diet-induced obese mice. The treatment reprogrammed white adipose tissue by enhancing lipid oxidation and reducing inflammatory and fibrotic pathways.

Hudson Biotech is recruiting for a Phase 2 trial of once-weekly retatrutide in 300 participants with obesity or overweight and weight-related comorbidities. The study compares multiple maintenance dose levels against placebo alongside diet and exercise counseling.

A review of Retatrutide research shows the drug can reduce HbA1c by up to 2.16% in type 2 diabetes patients and promote weight loss of up to 26.56% in individuals with obesity. Gastrointestinal side effects like nausea were noted more frequently at higher doses.

Researchers tested the triple agonist Retatrutide in obese mouse and hamster models, finding it improved metabolic health. In mice, it reduced body weight by 31%, while in hamsters, it lowered HOMA-IR and plasma triglycerides.

Eli Lilly and Company completed a Phase 3 trial involving 537 participants to investigate the efficacy and safety of once-weekly retatrutide compared to placebo for Type 2 diabetes patients with inadequate glycemic control. The study lasted about 11 months.

Eli Lilly and Company registered a Phase 3b trial to investigate the safety and efficacy of different dose escalation schemes for retatrutide in 600 adults without Type 2 diabetes who have obesity or overweight. The study duration is approximately 113 weeks.

Eli Lilly and Company registered a Phase 3b trial to evaluate the efficacy and safety of once-weekly retatrutide for weight reduction in 250 participants without Type 2 diabetes who have obesity or overweight. The study lasts about 65 weeks.

Eli Lilly and Company completed a phase 3 trial (NCT05931367) evaluating the efficacy and safety of once-weekly retatrutide in 445 participants with obesity or overweight and knee osteoarthritis.